This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ASM journals
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wildfeuer, A.
Right arrow Articles by Zimmermann, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wildfeuer, A.
Right arrow Articles by Zimmermann, T.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, 01 1996, 75-79, Vol 40, No. 1
Copyright © 1996 by the American Society for Microbiology. All rights reserved.

Uptake of azithromycin by various cells and its intracellular activity under in vivo conditions

A Wildfeuer, H Laufen and T Zimmermann
Department of Research and Development, Pfizer/Mack, Illertissen, Germany.

The concentrations of azithromycin in polymorphonuclear leukocytes (PMNLs), monocytes, erythrocytes, and plasma were measured in six healthy volunteers after the last treatment of a 3-day regimen of 500 mg once daily. Marked enrichment of azithromycin was found in PMNLs and monocytes. The drug concentrations after the last dose amounted to 114 +/- 43 (mean +/- standard deviation) mg/liter at 12 h in PMNLs and 34 +/- 17 mg/liter at 6 h in monocytes. Fourteen days thereafter, azithromycin was still detectable in the PMNLs at 53 +/- 34 mg/liter and in the monocytes at 1 +/- 2 mg/liter, although the drug was no longer detectable in plasma (< 0.02 mg/liter). Maximum drug concentrations for azithromycin in plasma (0.40 +/- 0.30 mg/liter) and erythrocytes (0.15 +/- 0.05 mg/liter) at 3 h after the last administration were much lower and occurred earlier than those observed in the phagocytic cells. The mean enrichment factors (cellular/extracellular ratios) of azithromycin in phagocytes relative to plasma came to 231 +/- 150 and 3,924 +/- 584 at 3 and 120 h, respectively, for PMNLs and 83 +/- 55 and 523 +/- 285 at 3 and 120 h for monocytes, respectively, after the last dose. The phagocytosis tests with PMNLs separated from the blood of volunteers at various times after the last treatment confirmed the enhanced intracellular activity of these cells against staphylococci.


This article has been cited by other articles:

  • Layegh, P., Yazdanpanah, M. J., Vosugh, E. M., Pezeshkpoor, F., Shakeri, M. T., Moghiman, T. (2007). Efficacy of Azithromycin versus Systemic Meglumine Antimoniate (Glucantime) in the Treatment of Cutaneous Leishmaniasis. Am J Trop Med Hyg 77: 99-101 [Abstract] [Full Text]  
  • Liu, P., Allaudeen, H., Chandra, R., Phillips, K., Jungnik, A., Breen, J. D., Sharma, A. (2007). Comparative Pharmacokinetics of Azithromycin in Serum and White Blood Cells of Healthy Subjects Receiving a Single-Dose Extended-Release Regimen versus a 3-Day Immediate-Release Regimen. Antimicrob. Agents Chemother. 51: 103-109 [Abstract] [Full Text]  
  • Beringer, P., Huynh, K. M. T., Kriengkauykiat, J., Bi, L., Hoem, N., Louie, S., Han, E., Nguyen, T., Hsu, D., Rao, P. A., Shapiro, B., Gill, M. (2005). Absolute Bioavailability and Intracellular Pharmacokinetics of Azithromycin in Patients with Cystic Fibrosis. Antimicrob. Agents Chemother. 49: 5013-5017 [Abstract] [Full Text]  
  • Tsai, W. C., Rodriguez, M. L., Young, K. S., Deng, J. C., Thannickal, V. J., Tateda, K., Hershenson, M. B., Standiford, T. J. (2004). Azithromycin Blocks Neutrophil Recruitment in Pseudomonas Endobronchial Infection. Am. J. Respir. Crit. Care Med. 170: 1331-1339 [Abstract] [Full Text]  
  • Danesi, R., Lupetti, A., Barbara, C., Ghelardi, E., Chella, A., Malizia, T., Senesi, S., Angeletti, C. A., Del Tacca, M., Campa, M. (2003). Comparative distribution of azithromycin in lung tissue of patients given oral daily doses of 500 and 1000 mg. J Antimicrob Chemother 51: 939-945 [Abstract] [Full Text]  
  • Butler, T. (2002). Reduction of MIC of azithromycin for Salmonella typhi and Staphylococcus aureus in broth exposed to previous growth of Salmonella typhi. J Antimicrob Chemother 50: 143-145 [Full Text]  
  • Mandell, G. L., Coleman, E. (2001). Uptake, Transport, and Delivery of Antimicrobial Agents by Human Polymorphonuclear Neutrophils. Antimicrob. Agents Chemother. 45: 1794-1798 [Abstract] [Full Text]  
  • Butler, T., Frenck, R. W., Johnson, R. B., Khakhria, R. (2001). In vitro effects of azithromycin on Salmonella typhi: early inhibition by concentrations less than the MIC and reduction of MIC by alkaline pH and small inocula. J Antimicrob Chemother 47: 455-458 [Abstract] [Full Text]  
  • Bui, K. Q., McNabb, J., Li, C., Nightingale, C. H., Nicolau, D. P. (1999). Mononuclear and Polymorphonuclear Leukocyte Dispositions of Clarithromycin and Azithromycin in AIDS Patients Requiring Mycobacterium avium Complex Prophylaxis. Antimicrob. Agents Chemother. 43: 2302-2304 [Abstract] [Full Text]  
  • Butler, T., Sridhar, C. B., Daga, M. K., Pathak, K., Pandit, R. B., Khakhria, R., Potkar, C. N., Zelasky, M. T., Johnson, R. B. (1999). Treatment of typhoid fever with azithromycin versus chloramphenicol in a randomized multicentre trial in India. J Antimicrob Chemother 44: 243-250 [Abstract] [Full Text]  
  • Girgis, N. I., Butler, T., Frenck, R. W., Sultan, Y., Brown, , Tribble, D., Khakhria, R. (1999). Azithromycin versus Ciprofloxacin for Treatment of Uncomplicated Typhoid Fever in a Randomized Trial in Egypt That Included Patients with Multidrug Resistance. Antimicrob. Agents Chemother. 43: 1441-1444 [Abstract] [Full Text]  
  • Cuffini, A. M., Tullio, V., Bonino, A., Allocco, A., Palarchio, A. I., Carlone, N. A. (1998). Entry of Sanfetrinem into Human Polymorphonuclear Granulocytes and Its Cell-Associated Activity against Intracellular, Penicillin-Resistant Streptococcus pneumoniae. Antimicrob. Agents Chemother. 42: 1745-1750 [Abstract] [Full Text]  


Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»